Weider focuses on eye health
This article was originally published in The Tan Sheet
Executive SummarySchiff Lutein will be "specially formulated with a higher level of zeaxanthin" than competing supplements because ingredient "is more concentrated in the middle of the fovea, where light impacts the retina," Salt Lake City-based Weider announces May 23. Eye health supplement contains 5 mg lutein, 1 mg zeaxanthin, as well as vitamins A, C, E, zinc and copper, and "helps promote healthy eyes by maintaining macular and retinal health," Weider says. Schiff Lutein will launch at food, drug and health stores nationwide in late spring; a 30-day supply will sell for $9.99-$15.99...
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.